Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/32392Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Wu, N | - |
| dc.contributor.author | Phelps, A | - |
| dc.contributor.author | Bain, T | - |
| dc.contributor.author | Bhuiya, AR | - |
| dc.contributor.author | Dass, R | - |
| dc.contributor.author | Sivanesanathan, T | - |
| dc.contributor.author | Whitelaw, H | - |
| dc.contributor.author | Wilson, MG | - |
| dc.date.accessioned | 2025-09-24T18:07:41Z | - |
| dc.date.available | 2025-09-24T18:07:41Z | - |
| dc.date.issued | 2025-03 | - |
| dc.identifier.citation | Wu N, Phelps A, Bain T, Bhuiya AR, Dass R, Sivanesanathan T, Whitelaw H, Wilson MG. Living evidence synthesis 25.2. Effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023–2024 season onwards. Hamilton: McMaster Health Forum, 17 March 2025. | en_US |
| dc.identifier.uri | http://hdl.handle.net/11375/32392 | - |
| dc.description.abstract | An in-depth synthesis of what is known, based on the best available research evidence from around the world (i.e., evidence syntheses) and local research evidence (i.e., single studies), about the effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023–2024 season onwards. | en_US |
| dc.description.sponsorship | This living evidence synthesis was commissioned and funded by the Office of the Chief Science Officer, Public Health Agency of Canada. | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartofseries | LES 25.2; | - |
| dc.subject | trivalent | en_US |
| dc.subject | quadrivalent | en_US |
| dc.subject | influenza | en_US |
| dc.subject | vaccines | en_US |
| dc.subject | infection | en_US |
| dc.subject | hospitalization | en_US |
| dc.title | Living evidence synthesis 25.2: Effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023–2024 season onwards | en_US |
| Appears in Collections: | Living evidence synthesis | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Living Evidence Synthesis 25.2 - Effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023-2024 season onwards.pdf | 608.41 kB | Adobe PDF | View/Open | |
| Living Evidence Synthesis 25.2 - Appendices.pdf | 776.97 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
